Viamet Pharmaceuticals is a biotechnology company specializing in the discovery and development of innovative therapeutics based on its metalloenzyme chemistry and biology expertise. Its clinical portfolio has included novel antifungal agents such as VT-1161 for indications like recurrent vulvovaginal candidiasis and onychomycosis, and the company also applies its metalloprotein inhibitor platform to other areas including infectious diseases, oncology, and orphan conditions.